Neoadjuvant chemoimmunotherapy for laryngeal preservation in locally advanced hypopharyngeal cancer.

Objectives: To retrospectively investigate the pathological response rate, laryngeal preservation surgery (LPS) rate and progression free survival (PFS) of neoadjuvant chemoimmunotherapy in the treatment of locally advanced hypopharyngeal cancer (LAHPC).

Materials And Methods: In this study, LAHPC patients, who were first diagnosed and underwent surgery at the First Affiliated Hospital of Naval Medical University between January 2021 and January 2024, preoperatively administered PD-1 inhibitor and TP induction regimen (albumin-bound paclitaxel 260 mg/m and cisplatin 80 mg/m). The primary endpoint was major pathological response (MPR), with ORR rate, LPS rate and PFS as the secondary endpoints.